

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313, 1420, on the date below:

March 9, 2005 Date

David L. Parker

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Isaiah J. Fidler

Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE

EFFICACY OF ANTICANCER

TREATMENTS

Group Art Unit: 1642

Examiner: Ungar, Susan NMN

Atty. Dkt. No.: UTSC:684US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

03/16/2005 EHAILE1 00000020 501212 10010763

01 FC:1806

5-00-0A

180.00 OF

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to

patentability as defined in 37 C.F.R. § 1.56(b).

A fee as set forth in 37 C.F.R. § 1.17(p) in the amount of \$180.00 is enclosed herewith. If an appropriate check has not been enclosed, or if it is insufficient, the Commissioner is authorized to deduct the appropriate fee from Fulbright & Jaworski Account No.: 50-1212/UTSC:684US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

David L. Parker Reg. No. 32,165

Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 474-5201

Date:

March 9, 2005

Form P	TO-144	9 (modified)	Atty. Docket	Atty. Docket No.			Serial No.		
				UTSC:684US	UTSC:684US 10/010,763				
List of P	atents an	nd Publications for	Applicant	Applicant					
\ INF			1 * * *	Isaiah J. Fidler					
1	ORMATIC	ON DISCLOSURE S	Corazon D. B	Corazon D. Bucana					
U.	(Una a		Filing Date:	-					
<u>;</u>)		several sheets if necessa		November 2, 2001 1642					
) U.	U.S. Patent Documents Foreign P				atent Documents			Other Art	
	See F	Page 1	See Page 1	e Page 1 See Page 1			ee Page I		
	-						·		
			U.S. Pat	ent Docum	ents				
Exam.	Ref.	Document	Date	Name	Cla	ss	Sub	Filing Date of	
lnit.	Des.	Number				(Class	App.	
		F	oreign P	atent Docu	ment	s			
Exam.	Ref.	Document	Date	Country	Cla		Sub Class	Translation Yes/No	
Init.	Des.	Number					Ciass	162/140	
					<u> </u>				
(Other	Art (Includir	ng Autho	r, Title, Date	e Per	tiner	nt Pag	ges, Etc.)	
Exam. Init.	Ref.	Citation							
	Des.								
	C34	Pollack et al. "Therapy of human carcinomas in athymic mice by inhibition of egf receptor-mediated signal transduction with cp-358774: dynamics of receptor inhibition and anti-tumor effects," Proc Annu Meet Am Assoc Cancer Res, Abstract 4249, 1997.							
	C35	Pollack et al., "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with cp-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>JPET</i> , 291739-748, 1999.							
	C36		th of human re	_	_		_	ptor antibody C225 e," Clinical Cancer	
	~~-	D	he biologic eff	ects of C225, a chi	meric n	onoclo	nal antib	ody to the egfr, on	
	C37	human prostate c	arcinoma," J o	f Immunotherapy,	19:419-	427, 19	97.		

25511056.1

Examiner:	DATE CONSIDERED:
-----------	------------------

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.